Entering text into the input field will update the search result below

Clene stock surges ~40% as CNM-Au8 shows promise in phase 2 multiple sclerosis trial

Feb. 13, 2023 9:28 AM ETClene Inc. (CLNN) StockBy: Ravikash Bakolia, SA News Editor

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs

gorodenkoff

Clene (NASDAQ:CLNN) said new data from a phase 2 trial in multiple sclerosis (MS) showed that CNM-Au8 treatment improved brain neuronal structural integrity.

The company reported updated MRI results from the phase 2 trial called VISIONARY-MS, 48-week treatment period

Recommended For You

More Trending News

About CLNN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CLNN--
Clene Inc.